Inhalon Biopharma announced that it has licensed human metapneumovirus (hMPV) antibodies from the University of Georgia and intends to develop inhaled hMPV antibodies for the treatment of hMPV respiratory infections. According to the company’s website, its pipeline includes a candidate designated IN-003 against hMPV.
Inhalon’s pipeline of inhaled therapies based on aerosolized “muco-trapping” antibodies also includes IN-006 and IN-007 for the treatment of SARS-CoV-2 infection. In 2021, the company partnered with Celltrion for development of a nebulized formulation of regdanvimab (IN-006)for the treatment of COVID-19 after receiving funding from the US Army for a Phase 1/2a study of the inhaled antibody against COVID-19.
Inhalon President and CEO John Whelan commented, “This agreement allows us to continue building a robust pipeline of potential treatments for acute respiratory infections on our innovative platform. Our team is committed to building upon our initial clinical successes with COVID-19 and advancing antibody treatments for a range of respiratory infections including RSV, influenza, and hMPV.”
Read the Inhalon Biopharma press release.
